Sanders Jason C, Muller Donald A, Dutta Sunil W, Corriher Taylor J, Ring Kari L, Showalter Timothy N, Romano Kara D
Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Front Oncol. 2021 Apr 29;11:664714. doi: 10.3389/fonc.2021.664714. eCollection 2021.
To investigate the safety and outcomes of elective para-aortic (PA) nodal irradiation utilizing modern treatment techniques for patients with node positive cervical cancer.
Patients with pelvic lymph node positive cervical cancer who received radiation were included. All patients received radiation therapy (RT) to either a traditional pelvic field or an extended field to electively cover the PA nodes. Factors associated with survival were identified using a Cox proportional hazards model, and toxicities between groups were compared with a chi-square test.
96 patients were identified with a mean follow up of 40 months. The incidence of acute grade ≥ 2 toxicity was 31% in the elective PA nodal RT group and 15% in the pelvic field group (Chi-square p = 0.067. There was no significant difference in rates of grade ≥ 3 acute or late toxicities between the two groups (p>0.05). The KM estimated 5-year OS was not statistically different for those receiving elective PA nodal irradiation compared to a pelvic only field, 54% 73% respectively (log-rank p = 0.11).
Elective PA nodal RT can safely be delivered utilizing modern planning techniques without a significant increase in severe (grade ≥ 3) acute or late toxicities, at the cost of a possible small increase in non-severe (grade 2) acute toxicities. In this series there was no survival benefit observed with the receipt of elective PA nodal RT, however, this benefit may have been obscured by the higher risk features of this population. While prospective randomized trials utilizing a risk adapted approach to elective PA nodal coverage are the only way to fully evaluate the benefit of elective PA nodal coverage, these trials are unlikely to be performed and instead we must rely on interpretation of results of risk adapted approaches like those used in ongoing clinical trials and retrospective data.
探讨采用现代治疗技术对宫颈癌淋巴结阳性患者进行选择性腹主动脉旁(PA)淋巴结照射的安全性和疗效。
纳入接受放疗的盆腔淋巴结阳性宫颈癌患者。所有患者均接受传统盆腔野或扩大野放疗,以选择性覆盖PA淋巴结。采用Cox比例风险模型确定与生存相关的因素,并通过卡方检验比较组间毒性。
共纳入96例患者,平均随访40个月。选择性PA淋巴结放疗组≥2级急性毒性发生率为31%,盆腔野组为15%(卡方检验p = 0.067)。两组≥3级急性或晚期毒性发生率无显著差异(p>0.05)。接受选择性PA淋巴结照射的患者与仅接受盆腔野照射的患者相比,KM法估计的5年总生存率无统计学差异,分别为54%和73%(对数秩检验p = 0.11)。
采用现代计划技术可安全地进行选择性PA淋巴结放疗,严重(≥3级)急性或晚期毒性无显著增加,但可能导致非严重(2级)急性毒性略有增加。在本系列研究中,未观察到接受选择性PA淋巴结放疗有生存获益,然而,该人群较高的风险特征可能掩盖了这一获益。虽然采用风险适应性方法进行选择性PA淋巴结覆盖的前瞻性随机试验是全面评估选择性PA淋巴结覆盖获益的唯一途径,但这些试验不太可能进行,因此我们必须依靠对正在进行的临床试验和回顾性数据中使用的风险适应性方法的结果进行解读。